Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate.
Dialysate effluent leukocytosis is consistent with a greater degree of infection or inflammation in patients receiving peritoneal dialysis. This study describes a girl aged 2 years 9 months with end-stage renal disease resulting from crescent glomerulonephritis and severe interstitial nephritis who developed leukocytosis with a predominance of lymphocytes in the dialysate effluent, and in whom the effluent cell count normalized 1 week after discontinuation of amlodipine besylate therapy. Rechallenge confirmed that amlodipine was the offending agent causing effluent leukocytosis.
Lee
Fan
F
Division of Nephrology, Yee Zen General Hospital and Asia Renal Care-Taiwan Branch, Yang Mei Town, Taoyuan, Taiwan, ROC.
Yu
Mei-Ching
MC
D017311:Amlodipine / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002675:Child, Preschool; D015314:Dialysis Solutions; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D007964:Leukocytosis / Q000139:chemically induced*; D010531:Peritoneal Dialysis, Continuous Ambulatory
D002121:Calcium Channel Blockers; D015314:Dialysis Solutions; D017311:Amlodipine